HOME >> MEDICINE >> NEWS
Study examines stenting options in diabetics

People with heart disease who also have diabetes pose specific challenges in treatment options due to the nature of their disease. A late-breaking clinical study presented today during the American College of Cardiology's inaugural Innovation in Intervention: the i2 Summit explores the outcomes of using two different types of drug-eluting stents in diabetics treated for heart disease. Innovation in Intervention: i2 Summit is an annual meeting for practicing cardiovascular interventionalists sponsored by the American College of Cardiology in partnership with the Society for Cardiovascular Angiography and Interventions.

Head-to-head studies have shown that drug-eluting stents infused with medicine to keep the artery from re-narrowing perform better than bare metal stents in patients treated for coronary artery disease. A 2005 study by Dr. Charles Simonton showed similar outcomes in the general population of patients for the two types of medicated stents currently being used in the United States.

Dr. Simonton and the STENT Group of eight coronary intervention centers have examined how the sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) performed in patients with diabetes. The STENT Group is the first prospective, consecutive, multi-center registry for drug-eluting stents in the U.S., which began enrollment in May 2003. More than 80 percent of all interventions are enrolled at the eight sites, with nine-month clinical follow-up achieved in 94 percent of patients.

A total of 1,680 diabetic patients undergoing either pure PES or pure SES procedures (i.e. no other vessels treated with other devices) were enrolled and completed nine-month follow up. Of the 498 insulin-treated diabetic patients, 235 received PES and 263 received SES. Of the remaining non-insulin-treated diabetic patients (1,182 pts), 570 received PES and 612 received SES. While PES-treated patients more frequently had high-risk or longer lesions and vessels
'"/>


13-Mar-2006


Page: 1 2

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study examines stenting options diabetics

(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, ... announced the two leaders who will deliver keynote presentations at the upcoming Digital ... Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver ...
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Beverly Hills, Luxury ... truly superb luxury vehicles based on which of the latest and greatest vehicles their ... step forward in pursuit of this goal: a 2015 Rolls Royce Wraith rental ...
(Date:9/2/2015)... ... September 02, 2015 , ... The Western ... and Mildred Goldstein Charitable Trust to establish the Abraham and Mildred Goldstein Endowment ... months after WCHN recruited nationally known gynecologic oncologist Thomas J. Rutherford, MD, PhD ...
(Date:9/2/2015)... ... 2015 , ... Date and time: Oct. 3, 2015, 9 a.m. to 4 ... Road, Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , The ... best-selling author Sam Keen based on his new book which he co-authored with his ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... safety and efficacy endpoint data collection, cloud analytics and workflow solutions today ... The series enables pharmaceutical researchers to participate in interactive programs in which ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3
(Date:9/2/2015)... , Sept. 2, 2015   About ELISA test ... common laboratory technologies that is used for measuring the ... solution. ELISA test uses various types of enzymes such ... the result is detected by photometry or fluorometry. ELISA ... of various infectious diseases such as HIV, pernicious anemia, ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ... Affairs in China (Basel, Switzerland - November 26-27, 2015)" ... provide a detailed overview of the key areas of pharmaceutical ... Hong Kong , Macau and ... - All important aspects of gaining and maintaining a ...
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP is ... trial will commence October 13, 2015. ... 510K fast-track approval program, Zimmer NexGen knee implant surpassed ... requires that companies provide evidence that the product is ... order to gain permissions. In 2001, ...
Breaking Medicine Technology:Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
Cached News: